Welcome to the e-CCO Library!

P485: Apolipoprotein C3 is Downregulated in Patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Hernandez Camba, A.(1);Carrillo Palau, M.(2);Ramos, L.(2);Alonso, I.(2);Vela, M.(1);Hernández, A.(2);Arranz , L.(1);Hernández, N.(2);Hernández-Guerra, M.(2);Ferráz, I.(3);
Created: Friday, 11 February 2022, 3:56 PM
P485: Development and implementation of a remote monitoring tool for real-world assessment of mild, moderate and severe infectious complications in Inflammatory Bowel Disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Rezazadeh Ardabili, A.(1,2);Wintjens, D.S.J.(1,2);Mujagic, Z.(1,2);Cilissen, M.(1);Stassen, L.P.S.(3);Haans, J.J.L.(1);Jonkers, D.M.A.E.(1,2);Pierik, M.J.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P485: Dosing infliximab in Crohn's disease: Is adjustment for body size justified?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Grisic A.-M.*1,2, Huisinga W.3, Reinisch W.4, Kloft C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P485: Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Vande Casteele*1,2, V. Jairath2,3,4, J. Jeyarajah2, P. S. Dulai1,2, S. Singh1, B. G. Feagan2,3,4, W. J. Sandborn1,2

Created: Friday, 22 February 2019, 9:41 AM
P485: Real-world evidence (RWE) on outcomes and clinical treatment patterns of 5-aminosalicylic acid (5-ASA) in mild Crohn’s disease (CD) from European healthcare databases (the CROHN’S investigation)
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Paridaens1, Y.L. Yip1, O. Ghatnekar2, M. Plassais1, J. Edwards3, J. Kuiper4, B. Rodgers-Grey3*, S. Buchan3

Created: Thursday, 21 February 2019, 9:14 AM
P485: The combined of mesenchymal stem cells and infliximab reduces the recurrence rate of Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

O. Knyazev1, N. Fadeeva*2, A. Kagramanova1, P. Shcherbakov3, I. Ruchkina1, A. Parfenov1, A. Konoplyannikov4

Created: Friday, 22 February 2019, 9:49 AM
P486 Assessing the efficacy of biologics in ucerative colitis: a real-life, observational retrospective multicentre study with propensity score analysis (AURORA): Focus on patients naive to biologics
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Cassinotti1, N. Mezzina1, D. Di Paolo2, M.V. Lenti3, C. Bezzio4, D. Stradella5, M. Mauri6, V. Zadro1, C. Cortellezzi7, C. Ricci8, V. Casini9, E. Radice10, A. Massari1, S. Ardizzone1, L. Pastorelli2, A. Di Sabatino3, G. Manes4, F. Caprioli11, M. Vecchi11, R. Tari5, P. Occhipinti5, M. Fichera6, P. Invernizzi6, M. Parravicini7, S. Segato7, F. Pace9, P.A. Testoni10, C. Tinelli12, A. De Silvestri12

Created: Thursday, 30 January 2020, 10:12 AM
P486: Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Sousa*1, A. Ponte1, J. Rodrigues1, J. Silva1, C. Gomes1, A. Rodrigues1, A. P. Silva1, J. Carvalho1

Created: Friday, 22 February 2019, 9:41 AM
P486: Immunization status of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cagol L.1, Frivolt K.2, Krahl A.3, Förster N.3, Lainka E.4, Gerner P.5, Ney D.6, Vermehren J.7, Trenkel S.8, Radke M.8, Koletzko S.2, Posovszky C.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P486: Improving enhanced recovery after surgery (ERAS): the effect of a patient-centred mobile application on patient participation in colorectal surgery
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van Der Storm, S.(1)*;Jansen, M.(1);Marsman, H.A.(2);Molly, G.P.(3);Consten, E.C.(4);Groot, L.M.(4);Boer, F.C.(5);Corver, M.(5);Oosterling, S.J.(6); Tuynman, J.B.(7);Bemelman, W.A.(1);Buskens, C.J.(1);Schijven, M.P.(1);
Created: Friday, 14 July 2023, 11:05 AM
P486: Intrapatient variability in adalimumab drug levels within and across cycles in Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Ward*1, 2, L. Beswick2, P. Thwaites1, J. Hogg1, G. Rosella3, J. Reynolds4, D. Van Langenberg2, P. Gibson1, 3, M. Sparrow1, 3

Created: Friday, 22 February 2019, 9:49 AM
P486: Iron deficiency anaemia in inflammatory bowel disease: Diagnosis, quality of life and iron treatment preferences among European patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Francis, D.(1);Hudson, O.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P486: Response to vedolizumab therapy in patients with inflammatory bowel disease: Impact of drug levels, anti-drug antibodies and α4β7 target occupancy
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Ungar1*, U. Kopylov1, M. Yavzori1, E. Fudim1, O. Picard1, A. Lahat1, D. Coscas1, M. Waterman2, O. Haj-Natour1, N. Orbach-Zingboim1, R. Mao3, M. Chen3, Y. Chowers4, R. Eliakim1, S. Ben-Horin1

Created: Thursday, 21 February 2019, 9:14 AM
P486: Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials
Year: 2022
Source: ECCO'22
Authors: Ungaro , R.(1);Siegel , C.A.(2);Cree , B.A.C.(3);Selmaj , K.W.(4,6);Ahmad , H.A.(5);Pai , A.(5);Ather , S.(5);Henry , A.(5);Charles , L.(5);Petersen , A.(5);Cheng , C.Y.(5);Afsari , S.(5);Sheffield , J.(5);Vaile , J.(5);Colombel , J.F.(1);
Created: Friday, 11 February 2022, 3:56 PM
P487 Development and validation of a new patient-reported outcome measure for Crohn’s perianal fistula: Crohn’s anal fistula quality-of-life (CAF-QoL) scale
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Adegbola1, L. Dibley2, K. Sahnan1, P. Tozer1, T. Wade3, A. Verjee4, R. Sawyer4, S. Mannick4, D. McCluskey4, N. Yassin1, R. Phillips1, C. Norton3, A. Hart1

Created: Thursday, 30 January 2020, 10:12 AM
P487: Anti TNF induced psoariasiform skin eruptions are increasing in in the biosimilar era – a descriptive study of drug induced skin manifestations and their management
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nu, K.P.(1)*;Stamp, K.(1);Shaji, S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P487: Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Pudilova1, M. Kolar1, D. Duricova*1, K. Malickova1,2, V. Hruba1, N. Machkova1, R. Vanickova1, K. Mitrova1, M. Lukas1, M. Vasatko1, M. Lukas1, M. Bortlik1,3,4

Created: Friday, 22 February 2019, 9:41 AM
P487: Effectiveness and safety of CT-P13 under routine care in paediatric patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Choe Y.H.*1, Yang H.R.2, Moon J.S.3, Ryoo E.4, Kim S.5, Lee J.H.6, Kim H.J.7, Park J.H.8, Kim M.J.9, Lee S.J.10, Lee S.Y.10

Created: Wednesday, 20 February 2019, 10:36 AM
P487: Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
Year: 2022
Source: ECCO'22
Authors: Chaparro, M.(1);Aguas, M.(2);Livne, M.(3);Rivière, P.(4);Bar-Gil Shitrit, A.(5);Myrelid, P.(6);Arroyo, M.(7);Barreiro-de Acosta, M.(8);Bautista, M.(9);Biancone, L.(10);Biron, I.A.(5);Boysen, T.(11);Carpio, D.(12);Castro, B.(13);Dragoni, G.(14);Ellul, P.(15);Holubar, S.D.(16);de Jorge, M.Á.(17);Leo, E.(18);Manceñido, N.(19);Moens, A.(20);Ramírez de la Piscina, P.(21);Ricanek, P.(22);Sebkona, L.(23);Sempere, L.(24);Teich, N.(25);Gisbert, J.P.(1);Julsgaard, M.(26);
Created: Friday, 11 February 2022, 3:56 PM
P487: The effect of a coordinated care programme for inflammatory bowel diseases on health care utilisation
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

W. K. van Deen*1, M. Skup2, A. Centeno1, N. Duran1, P. Lacey1, D. Jatulis3, E. Esrailian1, M. G. van Oijen4, D.W. Hommes1

Created: Friday, 22 February 2019, 9:49 AM